Saini Twinkle, Reny Jacky, Hennawi Hussam Al, Cox Andrew, Janga Chaitra, DeLiana Danila, McCaffrey James
Philadelphia College of Osteopathic Medicine, Philadelphia, PA, USA.
Thomas Jefferson University, Philadelphia, PA, USA.
Glob Cardiol Sci Pract. 2023 Jan 30;2023(1):e202302. doi: 10.21542/gcsp.2023.2.
First described in 2016, BRASH syndrome is an underreported clinical entity characterized by bradycardia, renal dysfunction, atrioventricular nodal blockade (AVNB), shock, and hyperkalemia. The recognition of BRASH syndrome as a clinical entity is crucial for early and effective management. Patients with BRASH syndrome present with symptomatic bradycardia that is resistant to treatment with standard agents such as atropine. In this report, we present the case of a 67-year-old male patient who presented with symptomatic bradycardia with an ultimate diagnosis of BRASH syndrome. We also shed light on predisposing factors and challenges encountered during the management of affected patients.
BRASH综合征于2016年首次被描述，是一种报道不足的临床病症，其特征为心动过缓、肾功能不全、房室结阻滞（AVNB）、休克和高钾血症。将BRASH综合征识别为一种临床病症对于早期有效管理至关重要。BRASH综合征患者表现为有症状的心动过缓，对阿托品等标准药物治疗无效。在本报告中，我们介绍了一名67岁男性患者的病例，该患者表现为有症状的心动过缓，最终诊断为BRASH综合征。我们还阐明了易感因素以及在管理受影响患者过程中遇到的挑战。
